Newsfeeds - Spark Newswire

5 minute read

FDA
News

Eagle Pharmaceuticals Says Vasopressin Shipments Scheduled To Commence Jan. 17, 2022; Says On Track To Submit New Drug Application In H1 2022, Seeking Approval Of Landiolol

Today, 11:35 AM

Eagle Pharmaceuticals Provides 2022 Business Update and Announces Launch of Vasopressin -- Vasopressin shipments scheduled to commence January 17, 2022 -- -- Together with upcoming launch of PEMFEXY™ and

EGRX

1 minute read

Eagle Pharmaceuticals Reports That Par Has Unilaterally Withdrawn Attempt To Halt Launch Of Vasopressin

By Benzinga Newsdesk

Today, 11:35 AM

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that Par Pharmaceutical, Inc. ("Par") has unilaterally withdrawn its request that the U.S. District Court

EGLX

1 minute read

Eagle Pharma Reports Received FDA Approval For Vasopressin

By Benzinga Newsdesk

Today, 11:35 AM

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s abbreviated new

EGRX

3 minute read

The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More

By Shanthi Rexaline

Today, 11:35 AM

Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound.

ABBV

6 minute read

Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates

By Shanthi Rexaline

Today, 11:35 AM

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for the year-to-date period to 45. This is just one short of NME approvals received for the same period last year.

ABBV

6 minute read

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data

By Shanthi Rexaline

Today, 11:35 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ACHV

1 minute read

Eagle Pharmaceuticals Q3 EPS $0.57 Misses $0.83 Estimate, Sales $39.90M Miss $46.40M Estimate

By Bill Haddad

Today, 11:35 AM

Eagle Pharmaceuticals (NASDAQ:EGRX) reported quarterly earnings of $0.57 per share which missed the analyst consensus estimate of $0.83 by 31.33 percent. This is a 51.28 percent decrease over earnings of $1.17 per share

EGRX

21 minute read

Earnings Scheduled For November 9, 2021

By Benzinga Insights

Today, 11:35 AM

Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.

AAIC

6 minute read

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout

By Shanthi Rexaline

Today, 11:35 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4)

ADTX

5 minute read

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO

By Shanthi Rexaline

Today, 11:35 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30)

ADMA